Beiersdorf Ag (BDRFF) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the Q3 results 2025 conference call of Beiersdorf AG. I'm Moritz, the call operator. I would like to remind you that all participants will be in a listen-only mode and the conference is being recorded. The presentation will be followed by a question and answer session. You can register for questions at any time by pressing star and one on your telephone. For operator assistance, please press star and zero. The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Christopher Sheldon, Head of Investor Relations. Please go ahead, sir. Good morning, everyone, and thank you for joining us for our third quarter conference call. I'm here with our CEO, Vincent Warnery, and our CFO, Astrid Herrmann. As always, we will start with the presentation of our sales performance of the quarter and the first nine months of the year, followed by a Q&A session. And with that, I'd like to hand over to Vincent. Thank you, Christopher, and good morning, everyone. Thank you for joining our conference call. Astrid and I will provide an overview of our sales performance and key developments of the third quarter and the first nine months of the year. The third quarter continued to be impacted by a very challenging market environment. Despite the headwinds, BioServe was able to improve its performance versus the prior quarter. Our Derma business continues to outperform, delivering outstanding double-digit growth and winning market shares across regions. In September, we also kicked off two major Nivea launches. In our face care franchise, we rolled out our breakthrough ingredient, epicillin. In our deodorant range, we launched a new derma control line. While the initial impact on Q3 was limited due to timing, these launches are a...